BREAKING
Messi set for final Argentina appearance after decorated international career‘EYES’ maker Manu Ashokan says ‘stalking deeply affects a person’s sense of safety’Pleasant_evenings_and_lucky-gem-casinos-netherlands_nl_offer_immersive_gaming_exHow much cinnamon a day is healthy for consumption? Doctor explainsAbhishek Sharma credits team support for fearless, impact-driven approachTemple wearable to launch in six colours, says Deepinder GoyalKényelmes megoldás törött kijelzőhöz és egyéb problémákhoz a https://phonerepairatx.com segítségével AustinbanIntéressant_divertissement_avec_betify_casino_online_et_opportunités_de_gainsSuhas’s Mandadi To Premiere On Netflix From October 8Jorge Jesus says Cristiano Ronaldo can return to Portugal squad if he wants
Lifestyle

GLP-1 drugs linked to improved survival in breast cancer patients with Type 2 diabetes, study suggests

hellohimachalse@gmail.com 24 Jul 2026 24 Jul 2026

New Delhi: Women living with both breast cancer and Type 2 diabetes may have better overall survival if treated with GLP-1 receptor agonists (GLP-1RA) after their cancer diagnosis, according to a new retrospective study. Researchers found that patients who received these diabetes medications had a significantly lower risk of death than those who did not. While the findings add to growing interest in the wider health benefits of GLP-1 drugs, the researchers stressed that more studies are needed before concluding their direct effect on breast cancer outcomes.

Study comparison and outcome

The retrospective study was conducted at City of Hope and included women with Type 2 diabetes who were diagnosed with breast cancer between 2009 and 2025. Researchers used a propensity score-matched design with a two-year landmark analysis to compare patients who received GLP-1 receptor agonists after their cancer diagnosis with those who did not.

After matching participants, the final analysis included 226 pairs of patients. Statistical methods such as multivariable Cox proportional hazards models and Kaplan-Meier survival analysis were used to assess overall survival and mortality risk.

Lower overall mortality observed among GLP-1 users

The analysis found that women who used GLP-1 receptor agonists after their breast cancer diagnosis had a lower risk of overall mortality than those who were not exposed to the drugs.

During the follow-up period, 47 deaths were recorded. Of these, 30 occurred among patients who had not received GLP-1 treatment, while 17 deaths were reported among those who had been exposed to the medication.

Researchers reported that GLP-1RA use was associated with a 49 per cent lower risk of overall mortality (hazard ratio: 0.51; 95 per cent confidence interval: 0.28–0.93; p=0.03).

Similar results seen in early-stage breast cancer

The association remained consistent when researchers focused only on women with stage I to III breast cancer.

In this subgroup, GLP-1 receptor agonist use was associated with an even lower mortality risk, with a hazard ratio of 0.45 (95 per cent confidence interval: 0.23–0.85; p=0.03), suggesting the survival benefit was not limited to the broader study population.

Kaplan-Meier survival analysis also showed improved overall survival among patients who received GLP-1RA therapy, with the difference reaching statistical significance (log-rank p=0.02).

More research needed before clinical conclusions

Although the findings suggest a potential survival benefit, the researchers cautioned that the study evaluated all-cause mortality rather than deaths specifically caused by breast cancer. As a result, it remains unclear whether the improved survival was directly related to cancer outcomes or to other health benefits associated with GLP-1 treatment.

The team concluded that further research is needed to better understand how GLP-1 receptor agonists may influence breast cancer outcomes, long-term survival and different causes of mortality in patients with Type 2 diabetes.

Related News